Serum amyloid A level as a marker of hepatocellular carcinoma in HCV-induced liver cirrhosis | ||||
| African Journal of Gastroenterology and Hepatology | ||||
| Volume 7, Issue 1, 2024, Page 304-310 PDF (414.79 K) | ||||
| Document Type: Original Clinical | ||||
| DOI: 10.21608/ajgh.2024.317322.1063 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Aliaa Samy Hindawy 1; Mohamed Gamal Abdrabou 2; Marwa Shawky Abdou 3; Mohamed AA Hussein  4
| ||||
| 1Clinical and Experimental Internal Medicine Department, Medical Research Institute, Alexandria university. | ||||
| 2Tropical medicine Department, Alexandria University, Alexandria, Egypt. | ||||
| 3Department of Epidemiology, High Institute of Public Health, Alexandria University. | ||||
| 4Internal Medicine Department, Faculty of Medicine ,Alexandria University,Alexandria ,Egypt. Internal medicine Department, Faculty of Medicine ,Beirut Arab University , Beirut,Lebanon. | ||||
| Abstract | ||||
| Aim: HCV-induced cirrhosis is recognized as a leading cause of Hepatocellular Carcinoma (HCC) with a high annual incidence in Egypt. The role of serum amyloid A (SAA) has been highlighted in many inflammatory and neoplastic diseases. Accordingly, this study aimed to evaluate the potential of SAA as a biomarker for HCC in patients with HCV-induced cirrhosis and its capacity to predict HCC. Patients and Methods: A comparative cross-sectional study was conducted on 90 HCV-induced cirrhotic patients. The patients were categorized into established HCC patients on top of HCV-induced cirrhosis (45 patients) and HCV-induced cirrhotic patients without HCC (45 patients). Besides taking history and conducting clinical, laboratory, and radiological examinations, SAA levels were recorded in all patients. Results: Compared to non-HCC patients, most of the laboratory results were significantly deteriorated in cirrhotic HCC patients. HCC is developed substantially in patients with class C Child Paugh scores (p< 0.001). The mean SAA is elevated considerably in cirrhotic HCC patients than in cirrhotic non-HCC patients (70.38 ± 57.12 vs. 6.84 ± 1.91 ng/mL, respectively). At a cut-off value of >12 ng/mL, the sensitivity and specificity of SAA were 93.33% and 100%, respectively SAA, to diagnose patients with HCC in HCV-induced cirrhosis. Conclusion: SAA is a highly sensitive and specific marker in diagnosing and predicting HCC development in HCV-cirrhotic patients. | ||||
| Keywords | ||||
| HEPATITIS C; LIVER TUMOR; LIVER CIRRHOSIS; HEPATIC TUMOR MARKERS; AMYLOID PROTEIN | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 210 PDF Download: 109 |
||||
